Adaptive Bio

Evidence of pricing power exists but is not absolute. The 2025 publication of a 2,007 dollar Medicare CLFS price for clonoSEQ and expanded coverage in DLBCL and MCL point to improving ASP and reimbursement durability. Score uplift.

Counterweights include the persistence of LDT competitors following the vacatur and rescission of FDA’s LDT rule and alternative modalities such as flow cytometry, which cap latent pricing.

Given MRD’s strong clinical utility and low test share of total cancer‑care economics, some future pricing room likely remains as evidence broadens, but we conservatively view pricing power as moderate rather than dominant.